share_log

Stoke Therapeutics Announces Plans To Present New Data That Support Zorevunersen As Potentially The First Disease-Modifying Medicine For Dravet Syndrome At The American Epilepsy Society 2024 Annual Meeting

ストークセラピューティクスは、アメリカ癲癇学会2024年年次総会において、ドラベ症候群に対する潜在的な初の疾患修飾薬としてゾレブネセンを支持する新しいデータを発表する計画を発表しました。

Benzinga ·  12/02 22:01

– Company to host a virtual educational event for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific) –

Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced several presentations at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6 – 10, in Los Angeles, California. In addition, the Company will host a virtual event with discussions led by leading clinicians and patient advocates for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific). The Company is advancing zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする